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Human T lymphocytes express receptors for antigen that are associated in a mo-
lecular complex to CD3 surface proteins . In most CD3+ cells these receptor mole-
cules are represented by disulphide-linked heterodimers formed by an a and a 0
chain that recognize antigen(s) in an MHC-restricted fashion (1, 2) . However, an-
other small subset has recently been identified that does not express a/R molecules
in association with CD3 (3, 4) . These cellsdo not react with theWT31mAb(specific
for a framework determinant of the TCRa/a) and do not express CD4 and CD8,
the molecules associated with class II or class I MHC antigen recognition (4) . In
these cells, C133-associated molecules are represented by the surface product of the
TCRy and -S genes (5-8).
Previous studies have indicated that TCRy/S+ cells, similarly to cells expressing
TCRa/R, can be activated by antibodies directed to surfaceCD3 or CD2 antigens
(9, 10) . However, no direct evidence exists that stimuliacting viathe surface receptor
itself would result in activation of the functional program of the cells . We have now
isolated amAb reacting with the surface receptor expressed on CD3+WT31 - cells
by immunizing with a cell h.ne derived from human peripheral T cells expressing
the CD3+WT31 -CD4-CD8- surface phenotype . This antibody, termed BB3,
reacts with a large subset (>60%) of CD3+WT31 - lymphocytes and im-
munoprecipitates from the surfaceof these cells adisulphide-linked dimer associated
to CD3 proteins . Treatment of CD3+WT31 - cells with BB3 mAb led to a rapid
intracellular Ca" increment and resulted in the induction of the functional pro-
gram(s) of the cells such as triggering of the lytic machinery and lymphokine
production .
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ACTIVATION OF CD3'WT31 - LYMPHOCYTES VIA TCRy
Materials and Methods
Isolation and Culture of CD3', CD4- , CDR Lymphocytes .
￿
Peripheral blood lymphocytes
from normal volunteers were isolated by Ficoll-Hypaque gradients and then separated into
E rosetting-positive and -negative populations. E-rosetting cells were then stained with a
mixture of anti-CD4 and anti-CD8 mAbs followed by treatment with rabbit complement
for 1 h at 37°C . Viable cells were cultured either at 10 5 cells/ml (for MVl cell population)
or under limiting dilution conditions (for T cell clones) in the presence of irradiated autolo-
gous PBL, as a source offeeder, 1% PHA (vol/vol) and 50 U/ml of rIL-2 in 96-well microtiter
plates. Cell lines and clones were screened directly by FAGS analysis, for the presence of
surface CD3 and the simultaneous lack ofCD4 or CD8 antigens. The mAbs used in these
experiments were Leu-4 (anti-CD3) (Becton Dickinson and Co., Basel, Switzerland), MAR
206 (directed to CD2), B9.4 (anti-CD8), CK.79 (anti-CD4), and WT31, specific for a frame-
work determinant of the TCR-a/0 . A polyclonal cell line, termed MV1, expressing the
CD2'3'4 - 8-WT31 - surface phenotype (>95% pure) was selected for mice immunization .
Production oftheBB3 mAb.
￿
6-wk-old male BALB/c mice were immunized with the MVl
cell line as previously described (11) . The immunization schedule consisted of three weekly
intravenous injection of 10 7 MVl cells . After 10 d, the mice received a booster injection of
1.5 x 10 7 cells followed by splenectomy 3 d later. Immune splenocytes were fused with P3-
Ul myeloma cells (11) . The initial screening of hybridoma supernatants (SN) was carried
out by indirect immunofluorescence against the immunizing MVl cell line or against
CD3'WT31' cell lines derived from the same donor. To this end cells were stained with hy-
bridoma supernatants (50 ul/10 5 cells) followed by fluoresceinated goat F(ab')2 anti-mouse
Ig as previously described (12) . According to this screening a hybridoma, termed BB3, that
reacted with MVl cells but not with CD3'WT31' cell populations, was isolated and fur-
ther subcloned by limiting dilution .
Two-Color Flow Cytofluorometric Analysis .
￿
Analysis of total PBMC for the distribution of
CD3, BB3, and WT31 antigens was performed using two-color fluorescence cytofluorometric
analysis, as previously described (13) . Cells were stained with phyroerythrin (PE)-conjugated
OKT3 (IgG2a) mAb (Ortho Pharmaceuticals, Raritan, NJ) and with either WT31 (IgG1)
(Sanbio Biological Products, Uden, The Netherlands) or BB3 (IgGl)mAb followed by FITC-
conjugated goat anti-mouse IgG1 antibodies (Southern Biotechnology Associates Inc., Bir-
mingham, AL) . After incubation at 4°C, cells were extensively washed in cold RPMI-1640
medium and then resuspended in the same medium supplemented with 5% FCS . Lympho-
cytes expressingCD3 but not WT31 orBB3 exhibited a red (PE) fluorescence, but no green
(FITC) fluorescence .
Characterization of the BB3 Antigen .
￿
MV1 or CD3'WT31
￿
cloned cells were washed five
times in cold RPMI-1640, twice in PBS and then surface-labeled with 1251 using the lac-
toperoxidase/glucose oxidase-catalyzed iodination (14). After labeling, cells were washed once
in PBS and resuspended at 0°C for 30 min in lysis buffer. The lysis buffer was as follows :
10 mM Tris-HCl (pH 7.5), 0.15 M NaCl, 1 mM EDTA, and 0.02% NaN 3 and contained
17o NP-40 or digitonin . Digitonin was added at 1 g/100 ml at the above solution, boiled,
stirred for 2 min, cooled, allowed to stand at room temperature for at least 4 d, and then
filtered . After spinning, the supernatants were filtered and dialyzed with PBS and precleared
three times with 20 pl of packed protein A-Sepharose beads for 2 h under rotation . Lysates
were then incubated for 2 h with 200 id ofBB3 culture supernatant or 50 wl of a 1 :10 dilution
ofanti-Leu-4mAb . 20 ttl of packed protein A-Sepharose beads were then added and samples
were incubated overnight at 4'C under rotation . The immunoprecipitate was eluted from
protein A-Sepharose by boiling for 5 min in buffer containing 1% SDS in the presence or
absence of5% 2-ME and analyzed on 11% discontinuous SDS-polyacrylamide gels (15) . The
nonequilibrium pH gradient electrophoresis (NEPHGE) was carried out using pH 3.5-10
ampholines followed by 11% SDS-PAGE gels for size separation as described (16) . The iodi-
nated sample was applied at the acidic end .
Functional Analysis of CD3' WT31 - Cell Papulalr'ons and Clones .
￿
Production of IL-2 from
clones and cell lines was assessed by culturing 10 5 cells/well in the presence of 2 ng/ml PMA
and either anti-CD3 mAb (10 wl of culture supernatant), or BB3 mAb (10 Al of culture su-
pernatant) . After 24 h, culture supernatants were removed and each tested in an indicatorCICCONE ET AL .
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cell system consisting of the IL-2-responsive murine CTLL cell line as described previously
(17) . Data were expressed as arbitrary units ofIL-2 activity . One unit was defined as the amount
of IL-2 required for the induction of a half-maximal proliferative response by CTLL cells .
The cytolytic activity of the clones was tested in a 4-h "Cr-release assay in which
CD3'WT31' or CD3'WT31 - cells were used as effector cells against the hybridomas
producing anti-CD3, anti-CD2, andBB3 mAbs, respectively. All these target cells were used
at 5 x 10 3 cells/well for a final E/T cell ratio of 10:1 . A second type of cytolytic assay was
performed using the murine P815 line as target cell (18) . In this assay 5 x 103 "Cr-labeled
target cells were added xo each well containing 5 x 103 effector cells in the presence of ei-
ther one of the following mAbs : anti-CD3 (20 ul ofculture supernatant), BB3 (20 p1 of cul-
ture supernatant) and WT31 (20 ul ofa 1 :20 dilution of the stock solution) . The final culture
volume was 0.2 ml for each well. After a 4-h culture period, 0 .1 ml was removed from each
well and counted in a gamma counter for the assessment of"Cr release. Percent specific
"Cr release was determined as previously described (19) .
Determination of Free Cytoplasmic Ca' Concentrate'on .
￿
Determination of [Ca2+ ] ; was per-
formed as previously described (20) . Briefly, CD3'WT31- cells were loaded with acetox-
imethyl ester of Fura-2 (1 wM final concentration) and the fluorescence of the cellular sus-
pension (105/2 ml) was monitored with an LS-5 spectrofluorimeter (Perkin-Elmer Corp.,
Pomona, CA) using 2 ml quartz cuvette . The cell suspension was excited at 340-380 nm
and fluorescence measured at 510nm . Five slit widths were used for both excitation and emis-
sion . All measurements were performed at 37'C using a thermostatically controlled cuvette
holder and stirring apparatus. [Ca2* ] ; were calculated by the method of Grynkiewicz et al .
(21) . In the Cat' depletion experiments, EGTA (final concentration 10 mM) was added to
the cellular suspension from a 500-mM stock (pH 7.4) 1-10 min before the addition of the
stimulatory mAb .
Results and Discussion
Cell Distribution ofBB3 Antigenic Determinant .
￿
A polyclonal CD3' 4- 8-WT31 - cell
line termed MVl was used for mice immunization . This cell line was derived from
peripheral blood lymphocytes depleted ofCD8' and CD4' cells by specific mAbs
and complement and cultured in the presence of rIL-2 . We have previously shown
that the C133-associated molecules expressed in this cell line are likely to be repre-
sented by the TCR-y/8 gene products (22) . Among the various hybridoma superna-
tants tested, one, termed BB3, reacted with the immunizing MV1 line but not with
a large panel ofTCR-a/R-bearing lymphocyte populations or clones . On the other
hand, large proportions ofCD3'WT31 - clones, derived from six different donors,
reacted with BB3 mAb. For example, 12 of 16 CD3'WT31 - clones derived from
one donor and 9 of 12 derived from another donor were BB3' . In addition, BB3
mAb reacted with variable, but usually small, percentages ofperipheral blood lym-
phocytes . These percentages ranged between 0.5 and 8% in 12 different individuals
tested and paralleled the percentages of CD3'WT31 - cells, as indicated by two-
color immunofluorescence experiments . A representative experiment is shown in
Fig . 1 : 7% ofPBMC were stained by anti-CD3 mAb but were unreactive with WT31
mAb. When thesame lymphocyte suspensionwas analyzed usinganti-CD3 in com-
bination with BB3 mAb, 6.6% of the cells were simultaneously stained by the two
mAbs . Moreover, BB3' cells were restricted to CD3' cell populations, since no
BB3' CD3 - cells could be detected . Taken together, these results indicate that most,
but not all, CD3'WT31" peripheral blood lymphocytes are recognized by BB3
rnAb . We next analyzed whether after interaction with the BB3 rnAb, BB3 surface
molecules would undergo modulation since such phenomenon has been shown to4
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FIGURE 1 .
￿
Distribution of BB3'
cells in peripheral blood lympho-
cytes. Peripheral blood lymphocytes
were stained withPE-OKT3 (anti-
C133) and FITC-BB3 (A) or with
PE-OKT3 and FITC-VVT31 (anti-
TCRa/p) (B), the contour plot was
divided into quadrants represent-
ing unstained cells (lower left), cells
with only red fluorescence (upper
left), cells with redand green fluo-
rescence (upper right), and cells
with only green fluorescence (lower
right) . 6.6% of lymphocytes were
simultaneously stained with OKT3
and BB3(A) and 7% ofcells were
OKT3' and WT31- (B).
occur after interaction ofTCR-a/0 or CD3 (23, 24) with the respective mAbs . We
found that BB3 antigenic determinant was susceptible to mAb-induced surfacemodu-
lation in a similar manner as CD3 molecules . Previous studies haveshownthatTCR
a/0 molecules undergo comodulation with CD3 after cell treatment with either anti-
TCR or anti-CD3 mAbs (24) . Similar studies performed in both MVl and several
CD3+ WT31 - clones indicated that antigen modulation induced by 13133 mAb
caused a simultaneous downregulation of surface CD3 molecules . Similarly, mAb-
inducedCD3 modulation led to the disappearance of 13133-reactive surface antigen
(datanot shown) . These data strongly suggest that the surface molecules recognized
by BB3 mAb in CD3+ WT31 - cells are physically linked to the CD3 molecular
complex .
Biochemical Characterization ofProteins Recognized by BB3 mAb.
￿
The BB3mAb im-
munoprecipitated from 1251 surface-labeled MVl cells an 80-kD surface protein
under nonreducing conditions and three bands of -44, 42, and 38kD underreducing
conditions (in the presence of 1% NP-40) (Fig. 2) . Similar figures were obtained
from all of the eight additional CD3 +WT31 -BB3+ clones analyzed: in all instances,
only disulphide-linked molecules couldbe precipitated (data not shown) . Under ex-
FIGURE 2 .
￿
SDS-PAGE analysis of surface molecules im-
munoprecipitated from the CD3'WT31 -BB3' cell line
MVl by BB3 and anti-CD3 . -15 x 106 MVl cells were
surface labeled with 125 I using the lactoperoxidase tech-
nique . One-third of the labeled cells were lysed in buffer
containing 1 g/100ml digitonin and the remainingcellswere
lysed in buffer containing 1% NP-40 . Lysates were pre-
clearedand then immunoprecipitationwasperformed with
either anti-Leu-4 (anti-CD3) or BB3mAbs coupled topro-
teinA-Sepharose beads. MVl cells werelysed in NP-40and
immunoprecipitated by BB3mAbunder nonreducing con-
ditions (lane a) or under reducing conditions (lane b) . The
same cells were alsolysed in digitonin-containing buffer and
immunoprecipitated byanti-Leu-4 rnAb under nonreducing
conditions (lane c) or under reducing conditions (lane d) .
In lane e, cells werelysed in digitoninandimmunoprecipi-
tated with BB3 mAb under reducing conditions.CICCONE ET AL .
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FIGURE 3 .
￿
NEPHGE analysis ofthe TCR molecular complex present on the CD3*4- 8-WT31-
clone 6.6 .1 . In the left panel, 1251-labeled 6 .6 .1 cells were lysed under conditions that preserve
theCD3TCR complex association (1% digitonin) and were immunoprecipitated with anti-Leu-
4 (anti-CD3mAb). Inthe right panel, theCD3TCR molecular complex was dissociated by lysing
the same cells in buffer containing 1% NP-40 . The lysate was then immunoprecipitated by using
the BB3 mAb . Samples were analyzed by NEPHGE . In the second dimension, 11% acrylamide
gels were used for SDS-PAGE analysis.
perimental conditions that preserve theTCR/CD3 association (lysis in the presence
of 1% digitonin), the BB3 mAb coprecipitated the three bands above together with
CD3 molecules . Similar figures were obtained when the same cell lysate was im-
munoprecipitated with anti-CD3 mAb . The identity between the 44-, 42-, and 38-
kD molecules precipitated by BB3 mAb and those precipitated by anti-CD3 mAb
wasconfirmed in two-dimensional electrophoresis experiments (using pH-dependent
separation in the first dimension followed by size separation in the second dimen-
sion, NEPHGE) (17) . As shown in Fig. 3, in a BB3* clone, the CD3-associated
molecules immunoprecipitated by anti-CD3 mAbdisplayed the same electrophoretic
mobility as the molecules immunoprecipitated by BB3 mAb. It is evident that, in
both instances, immunoprecipitated molecules were represented by a 44-kD mole-
cule displaying a basic pI (ti7.5) and by two more acidic proteins (pI N6) with a
mol mass of -42 and 38 kD. Similar data have been reported by Lanier et al. (8)
by immunoprecipitation experiments using an anti-CD3 mAb on a CD3'WT31 -
cell population . The finding that in immunoprecipitation experiments performed
underconditions thatdo not preserveTCRCD3 interactions (1% NP40) BB3 mAb
only precipitated TCR proteins and notCD3 molecules, strongly suggests that the
antigenic determinant recognized by BB3 is present onTCR7/8 and not on CD3
molecules .
BB3 mAb Induces CD3' WT31- Lymphocytes to Express thet'r Functt'onal Pro-
gram. Previous studies have indicated that CD3'WT31 - cells, similarly to con-
ventional CD3'WT31' (TCRa/P') lymphocytes respond to a series of stimuli in-
cluding PHA, anti-CD3 mAb, and appropriate combinations of anti-CD2 mAbs
(9, 10) . T cell responses resulted in activation ofthe cellular functional program in-
cluding lymphokine production and triggering of the lytic machinery. Although theACTIVATION OF CD3+WT31 - LYMPHOCYTES VIA TCR-y
TABLE I
IL-2 Production Induced by Anti-CD3 or Anti-TCR-yIS Antibodies
106/ml cells were cultured in the presence of a final concentration of 1 :20
hybridoma supernatant and 2 ng/ml of PMA. After 24 h supernatants were
collected and tested for IL-2 activity using the CTLL indicator system. Data
are expressed as arbitrary units ofIL-2 activity as described in Materials and
Methods.
x Cells were represented by MV1 polyclonal cell line, used for mice immuniza-
tion, or by cloned cells.
induction ofT cell responses by anti-CD3 mAb suggested the existence of a func-
tional activation pathway initiated by CD3/TCR complex, no direct proofexisted
that the TCRy/S itself was capable ofdeliveringactivation signals to the cell. Thus,
we investigated whether TCR-y/8' clones, as well as the immunizing MVl cell line,
could be triggered by the BB3 mAb to release IL-2. As shown in Table I, three
CD3+WT31 -BB3+ clones and the MV1 cell line, which produced IL-2 after stim-
ulationwith anti-CD3 mAb, released similar amounts ofIL-2 also after stimulation
with 13133 mAb. On the other hand, the remaining clone did not release IL-2 with
neither anti-CD3 nor BB3 mAb. Moreover, 13133 mAb failed to activate two
TABLE II
Lysis of mAb secreting hybridomas, by CD3+ WT31- or
CD3+ WT31+ effector cells
Effector cells were represented by MV1 polyclonal cell line or by cloned cells.
Data are expressed as percent S'Cr release from labeled hybridoma target cells
at a 10:1 E/T cell ratio.
5 Note that in this experiment only a single anti-CD2 mAb (MAR 206) was used.
We have previously shown that CD3' WT31 - cells can be activated via sur-
face CD2 molecules only in the presence of two appropriate anti-CD2
mAb-producing hybridomas .
Cells Surface phenotype
IL-2 production
stimulation with
Anti-CD3 13133
upon
mAbs'
None
MV11 CD3+ 4- 8- WT31 - BB3* 11 10 0
M 4.3 CD3+4- 8- WT31 - BB3' 12 10 0
M 2 .1 CD3+ 4- 8- WT31 - BB3' 24 22 0
T 2.1 CD3+4- 8- WT31 - BB3+ 16 8 0
MV113 CD3+ 4- 8- WT31 - BB3+ 0 0 0
T 12 CD3+ 4+8- WT31+BB3- 11 0 0
T 1 CD3+4- 8+WT31+BB3- 36 0 0
Effector
cells Surface phenotype
Hybridoma target cells
Anti-CD3 13133 Anti-CD29
MV1' CD3+ 4- 8- WT31 - BB3+ 561 96 0
M 4.3 CD3+ 4- 8- WT31 - BB3+ 81 91 7
M 2.1 CD3+4- 8- WT31 - BB3+ 43 89 0
T 2.1 CD3'4- 8- WT31 - BB3+ 84 91 1
MV113 CD3+4- 8- WT31 - BB3' 65 83 7
T 12 CD3'4+8- WT31+BB3- 36 0 0
T 1 CD3'4- 8+WT31+BB3- 42 0 0CICCONE ET AL.
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TABLE III
mAb-induced Lysis of P815 Target Cells by CD3' WT31- or CD3' WT31+ Efector Cells
The cytolytic test against 5'Cr-labeled P815 murine mastocytoma cells was performed as
described in Materials and Methods.
The various antibodies were added at the onset of the cytolytic test.
$ Effector cells were represented by MV1 polyclonal cell line or by cloned cells.
5 Data are expressed as a percent specific 51Cr release at 1 :1 E/T ratio.
CD3+ WT31' (TCRa/a+) clones that produced IL-2 after stimulation with
anti-CD3 .
Given the ability ofCD3+WT31 - clones and populations to lyse target cells after
stimulation with mAbs directed to the CD3/TCR molecular complex (9), we inves-
tigated whether activation ofthe lytic machinery could also be induced by BB3 mAb.
To this end, we used as triggering target the hybridoma producing BB3 mAb. As
shown in Table II, all the CD3+WT31 - BB3+ cells analyzed efficiently lysed the
BB3-producing hybridoma as well as an anti-CD3 hybridoma. On the contrary, no
lysis occurred when a single anti-CD2 mAb-producing hybridoma (mAb 206) was
used. In fact, as previously shown, the activation of the CD2 pathway requires the
combined use of suitable anti-CD2 mAbs and does not occur when the signal is
given by a single anti-CD2 mAb (25).
To further define the ability of BB3 mAb to trigger the lytic machinery of TCR
y/S+ cells, we used a cytolytic assay in which P815 target cells (which express sur-
face Fc-y receptors) are lysed by CD3+ cytolytic cells provided that soluble anti-
CD3 mAb is present (18). As shown in Table III, BB3 mAb was as efficient as anti-
CD3 mAb in inducing lysis of P815 cells by TCRy/S+ clones and MVl cell line.
The CD3' WT31' cytolytic clone used as control did not lyse P815 in the presence
of BB3 but did so in the presence of WT31 mAb.
We have also investigated the role of free cytoplasmic Cal' levels in the trans-
duction of signals induced after cell stimulation with BB3 mAb. In previous studies
(10) we demonstrated that signaling via either CD3 or CD2 surface molecules resulted
in a rapid increase of free intracytoplasmic Cal' levels in both CD3+WT31 - and
CD3 + WT31+ lymphocytes. In addition, experiments performed in the presence of
the Cal' chelator EGTA indicated that the [Ca2+ ]i raise was consequent to an early
release from the internal stores followed by a more sustained Call influx from the
extiacellular compartment (10). Here we show that triggering of surface TCR molecules
of CD3+WT31 - lymphocytes by BB3 mAb induces a rapid increase of [Ca2+ ] ;
levels, followed by a plateau phase (Fig. 4 B). Similar events occurred when cells
were stimulated by anti-CD3 antibodies (Fig. 4 A). Although not shown, experi-
ments of Cal' mobilization performed in the presence of EGTA confirmed that BB3
Effector cells Surface phenotype
mAb added to the
Anti-CD3 WT31
cytolytic
BB3
test'
None
6.6.11 CD3'4- 8- WT31- BB3' 825 2 81 3
6.25.4 CD3'4- 8- WT31 - BB3' 77 4 64 4
5.25.10 CD3+4- 8- WT31 - BB3' 89 1 78 1
MV1 CD3'4- 8- WT31 - BB3* 83 5 84 6
5.50.1 CD3' 4- 8' WT31 *BB3- 64 51 3 38
￿
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FIGURE 4.
￿
Comparative analysis of [Ca2+ ); mobiliza-
tion in 6.6.1 cloned CD3'WT31 - BB3' cells in re-
sponse to anti-CD3 (A) or BB3 (B) mAb. Cloned cells
were loaded with acetoxymethyl ester Fura-2 as described
in Materials and Methods. Stimuli were added in the
presence of 1 mM extracellular Ca21 . The arrows in-
dicate the time of the addition of the stimuli.
mAb induced both a rapid Ca2+ release from the internal stores followed by an
influx from the extracellular compartment.
Our present data provide evidence that stimuli that act directly on the TCR-y/8
molecules are capable ofinducing TCR-y/8' cell activation. Similarly to TCRa/a,
the early events that follow ligand-receptor interaction are represented by a rapid
[Ca2+ ]; increase that reflects sequential Ca2+ mobilization from intracellular and
extracellularcompartments. In addition, functional analyses revealed that BB3 mAb
induced, in CD3' WT31 -BB3+ cells, both triggering ofthe cytolytic machinery and
production of IL-2. Therefore, it is conceivable that upon binding to TCRp/S, a
natural ligand (antigen?) may similarly trigger CD3+WT31 - BB3+ cells to express
their functional program. Along the same line, an antibody described by Moingeon
et a]. (5), reactive with a clonotypic determinant of afetal TCRy/S+ clone, inhibited
the cytolytic activity of this clone against the NK-sensitive K562 target cells and
induced proliferation of the same clone in the absence of exogenous IL-2 (5). More
recently, the same groupdescribed a second antibody (Ti-YA) directed to the TCR-
y/8 of adult T lymphocytes (26). Although no functional data have been reported,
Ti-yA mAb appears to be similar to BB3 since it recognized TCRy/8 molecules
expressed by the majority of CD3+WT31 - peripheral lymphocytes and cell clones.
However, a remarkable difference between the two antibodies is represented by the
reactivity of the Ti-yA antibody with the TCRy/S proteins, independently upon
the Cy gene segment used, whereas BB3 reactivity appears to be restricted to cells
that express the disulphide-linked form of the TCRy/S . It is noteworthy that the
majority of CD3+WT31 - clones obtained under our experimental conditions dis-
played the disulphide-linked form of the TCR molecules, in which the y chain is
represented by the molecular product of Cyl gene segment (5, 8, 27), and reacted
with BB3 mAb. In contrast, less than one-third expressed thenon-disulphide-linked
form of the TCR and were not BB3 reactive. In this context, the PEER leukemic
cell line, known to express the molecular product of the Cy2 gene (that is
non-disulphide-linked to 8 chain) (27) did not react with BB3 mAb. Therefore, the
BB3 mAb allows us to further dissect the CD3+WT31 - cell subset and the two
populations so defined may correspond to cells that express different TCRy/S types.
Summary
In an attempt to select mAbs specific for human TCR-y/S, a polyclonal
CD3+4-8-WT31 - (TCRy/S+ ) cell line (MVI) was used for mice immunization.An mAb, termed BB3, reacted with MV1 cells but not with a large panel of
CD3'WT3;1' (TCRa/S')cell populations or clones. Inaddition, BB3 mAb reacted
with the majority ofCD3'WT31- clones derived from six different donors. Double-
color fluorescence experiments and FACS analysis showed that BB3+ cells were re-
stricted to the CD3+ fraction ofperipheral blood lymphocytes; in addition, in several
donors the percentages (0.5-8% of total PBL) of BB3+ cells paralleled those of
CD3'WT31- cells. Surface molecules recognized by BB3 were susceptible to
antibody-induced modulation; in addition, cell treatment with either BB3 or anti-
CD3 mAbcaused thesimultaneous downregulation ofthetwo molecules. ThatBB3
molecules are physically linked to CD3 antigen was further supported by im-
munoprecipitation experiments. Thus, under conditions that preserve the TCR-
CD3 association, both BB3 and anti-CD3 mAb precipitated from "'I-labeled MVI
cells the same set of molecules. These consisted in the 18-28-kD CD3 molecules
and in three bands of -44, 42, and 38 kD under reducing conditions. When cell
lysis was performed in 1% NP-40, the molecules immunoprecipitated by BB3 mAb
were represented by an 80-kDband under nonreducing conditions, which resolved;
under reducingconditions, inthethree 44-, 42-, and 38-kDbands. Similardisulphide-
linked forms of the TCR molecules were revealed in all of the other eight
CD3'WT31-BB3+ clones analyzed. Analysis ofTCR molecules by electrophoresis
(NEPHGE) showed that 13133 oranti-CD3 precipitated a44-kDmolecule displaying
a basic PI (-7.5) and two more acidic proteins (PI N6) with a mol mass of 42 and
38 kD. Studies aimed to define whether stimuli directly acting on TCRy/S could
induce CD3'WT31 - cell activation revealed that (a) In the presence of PMA,
soluble BB3 mAb induced IL-2 production by MVl cell line and by three other
CD3'WT31 -BB3' clones analyzed. (b) BB3 mAb-producing hybridoma used as
triggering target, was efficiently lysed by CD3'WT31-BB3' effector cells (but not
by CD3'WT31'BB3- conventional CTL). (c) Soluble 13133 mAb induced
CD3'WT31- BB3' efector cells to lyse the Fc receptor-positive P815 target cells.
(d) BB3TCR7/S interaction on CD3'WT31-BB3' cells induced a rapid increase
of [Ca2']; levels, similar to that observed in response to anti-CD3 mAbs.
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